Last updated: May 26, 2026
Daridorexant hydrochloride is supplied through a mix of API manufacturers and finished-dose marketers. In practice, supply chains for this orexin receptor antagonist depend on whether you source (1) the active pharmaceutical ingredient (API) daridorexant hydrochloride, (2) key intermediates for daridorexant synthesis, or (3) finished tablets (U.S. FDA NDA product by Eisai). Vendor selection also turns on regulatory status (DMF type, CEP availability) and whether the supplier is already qualified to support commercial manufacturing or only provides R&D-grade material.
Which companies supply daridorexant hydrochloride API for commercial manufacturing?
A complete supplier list requires mapping daridorexant hydrochloride to specific DMFs/letters of authorization and Orange Book manufacturing site references. That mapping is not available in the provided inputs, and a full, accurate supplier roster cannot be produced without it.
What supplier categories exist for daridorexant hydrochloride?
Commercial sourcing typically breaks into four bins:
- API suppliers filing or supporting daridorexant hydrochloride DMFs (Type II/III depending on jurisdiction and site).
- Intermediate suppliers producing regulated precursors used in daridorexant synthesis.
- Contract manufacturers making finished tablets from supplied API (site-specific cGMP).
- Finished-dose distributors that market the NDA product into wholesalers and hospitals.
What regulatory artifacts determine whether a supplier is “real” for U.S. supply?
For U.S. manufacturing, the practical proof points are:
- FDA DMF status for daridorexant hydrochloride (and relevant intermediates).
- cGMP inspection history for the specific manufacturing site.
- Inclusion in the commercial manufacturing supply chain for the NDA dosage form.
- Where applicable, linkage to ANDA or 505(b)(2) submissions that reference the same API supplier.
Are there approved DMF-listed suppliers for daridorexant hydrochloride in the U.S.?
A supplier answer requires pulling FDA DMF listings tied to daridorexant hydrochloride. That dataset is not present here, so a definitive DMF-listed supplier list cannot be generated.
How to interpret “DMF supplier” when buying daridorexant hydrochloride
When sourcing API, the “supplier” is often:
- the company named on the DMF cover letter,
- plus the specific API manufacturing site referenced within the DMF,
- which may differ from the brand or the trading company.
Which companies make daridorexant finished tablets in the U.S. (commercial supply)?
Finished daridorexant tablets are marketed under Eisai’s brand for insomnia (the NDA holder and commercial marketer). Identifying the contract manufacturing organization (CMO) sites for tablet production requires Orange Book manufacturing site references and/or the NDA’s facility disclosure. That information is not supplied.
What determines tablet manufacturing site eligibility
Tablet supply is constrained by:
- validated formulation and scale-up at the designated cGMP facility,
- packaging and labeling controls for the U.S. market,
- technology transfer history and audit readiness,
- and any site-specific IP or process agreements.
Which companies supply daridorexant intermediates used in API synthesis?
Intermediate sourcing is common for regulated APIs, but a credible intermediate supplier list requires:
- vendor disclosure from master batch records,
- DMF descriptions,
- or independent filings referencing the same synthetic route.
None of those source datasets are included, so an accurate intermediate supplier list cannot be produced.
What is the typical sourcing model for daridorexant hydrochloride API and intermediates?
In regulated CNS API supply chains, daridorexant hydrochloride sourcing usually follows one of these models:
-
Single primary API supplier with backup
A main API vendor supports commercial demand, with a qualified second vendor to mitigate supply disruption.
-
API sourced from one supplier, intermediates from multiple
API manufacturer controls final synthesis and release testing, while upstream intermediate steps come from additional suppliers.
-
CMO-manufactured finished tablets sourced from a small number of tablet sites
Even if API is broadly available, finished-dose manufacturing is tighter due to formulation IP, stability data, and validated process parameters.
How does daridorexant hydrochloride supply risk affect launch timing for generics and 505(b)(2) products?
Supply risk is driven by:
- the number of DMF sites that can legally supply the market,
- whether API quality systems support commercial release,
- and whether alternative routes can pass impurity and polymorph specifications.
A launch risk assessment requires the specific Orange Book patent and regulatory exclusivity timeline, plus the existence of alternative API/CMC capabilities. That timeline and the alternative CMC pathways are not provided here.
What patents or Orange Book listings affect sourcing decisions for daridorexant hydrochloride?
Sourcing can be affected by:
- process patents protecting key intermediates or synthetic steps,
- polymorph and formulation patents (if relevant to the supplier’s downstream stage),
- and method-of-use patents that determine whether a competitor must design around.
A correct patent-and-exclusivity mapping requires Orange Book listing retrieval for daridorexant’s NDA and patent estate analysis, which is not available in the provided inputs.
Key Takeaways
- Daridorexant hydrochloride supply involves API suppliers, intermediate suppliers, and cGMP finished-dose tablet manufacturers, but a definitive “who supplies it” list cannot be produced from the information provided here.
- U.S.-market credibility for a supplier is established through FDA DMF/inspection realities and the NDA/Orange Book-linked manufacturing sites, not through generic manufacturer catalogs.
- Supplier selection for daridorexant depends on both CMC qualifications (API release, impurity profiles, stability) and any process/formulation/IP constraints that can impact commercialization.
FAQs
- How do I verify a daridorexant hydrochloride API supplier is FDA-approved for U.S. commercial use?
- What documentation is typically required to qualify a daridorexant hydrochloride API supplier (CoA, CEP/DMF, impurity specs)?
- Can a daridorexant hydrochloride intermediate supplier support cGMP API manufacturing without an approved DMF?
- What CMC changes most often trigger regulatory delays when switching daridorexant API suppliers?
- How do polymorph and impurity specifications constrain sourcing for daridorexant hydrochloride API?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA database).
- FDA Drugs@FDA. U.S. Food and Drug Administration. (Accessed via Drugs@FDA database).
